The IFI27 antibody targets the interferon-alpha-inducible protein 27 (IFI27), a member of the ISG12 family encoded by the IFI27 gene. This gene is highly responsive to type I interferons (IFNs) and is upregulated during viral infections, inflammatory responses, and cellular stress. IFI27 plays a role in apoptosis, immune regulation, and antiviral defense, though its precise mechanisms remain under investigation. Studies suggest it may promote mitochondrial-dependent apoptosis by interacting with BCL-2 family proteins, influencing cell survival during infections or inflammatory conditions.
IFI27 is implicated in various diseases. Elevated expression is observed in chronic viral infections (e.g., HIV, HCV), autoimmune disorders, and cancers, including liver, breast, and lung malignancies. Its overexpression in tumors often correlates with poor prognosis, suggesting potential as a diagnostic or prognostic biomarker. In viral contexts, IFI27 may limit viral replication but could also contribute to tissue damage through excessive apoptosis.
The IFI27 antibody is widely used in research to detect protein expression in tissues or cells, aiding studies on viral pathogenesis, cancer biology, and immune responses. Commercial antibodies are validated for techniques like Western blot, immunohistochemistry, and flow cytometry. However, discrepancies in reported functions highlight the need for further research to clarify its roles and therapeutic potential. Its dual pro- and anti-inflammatory effects underscore the complexity of IFI27 in disease contexts.